Product
Phase Ib ARRY-614 + nivolumab
1 clinical trial
5 indications
Indication
Renal Cell CarcinomaIndication
MelanomaIndication
Solid TumorIndication
Lung CancerIndication
Head and Neck Squamous Cell CarcinomaClinical trial
A Phase Ib/II Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab in Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2027-11-21